In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

NEW YORK – Elicio Therapeutics earlier this week said it has reached an agreement with the US Food and Drug Administration on a planned Phase III trial and registrational strategy for its ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

NEW YORK – Belief BioMed announced Wednesday that the US Food and Drug Administration has cleared its investigational new drug application enabling it to begin testing its gene therapy candidate for ...

NEW YORK – Scientists are working to better understand the role of germline pathogenic variants in the development of ductal carcinoma in situ (DCIS) and whether germline variants influence which ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.